Zobrazeno 1 - 10 of 41 pro vyhledávání: '"Wijith, Munasinghe"'
1
Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir
Autor: Nael M. Mostafa, Bhadrish K. Vallabh, John B. Morris, Michael F. Jarvis, Ahmed M. Saeed, Jeffery M. Schmidt, Wijith Munasinghe
Publikováno v: Journal of Pharmaceutical Sciences. 110:3963-3968
Background Lopinavir/ritonavir (LPV/r-A, Kaletra®), a fixed dose, co-formulated antiviral therapy for the treatment of HIV infection has been used worldwide for over two decades. Both active substances have low solubility in water and low membrane p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8cf705d3d2a30acb72007ce364fffc3
https://doi.org/10.1016/j.xphs.2021.08.037
Zobrazit plný text záznamu
3
A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
Autor: Fook-Thean Lee, Peter Ansell, Hao Xiong, Benjamin Solomon, Marika Ciprotti, Andrew M. Scott, JuDee Fischer, Edward B. Reilly, Rod A. Humerickhouse, Wijith Munasinghe, Matthew Burge, Yumin Zhang, Kyle D. Holen, Hui K Gan, Sze Ting Lee, Gerard B. Fox
Publikováno v: Journal of Nuclear Medicine. 62:787-794
ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution, and pharmacokinetics of 111In-radiolabeled ABT-806 (ABT-806i) and effects of repeated doses of ABT-806 on recepto
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7472922bfd2468777ca7450742cddebb
https://doi.org/10.2967/jnumed.120.253146
Zobrazit plný text záznamu
5
A Phase 1 and Biodistribution Study of ABT-806i, an
Autor: Hui K, Gan, Matthew, Burge, Benjamin, Solomon, Sze Ting, Lee, Kyle D, Holen, Yumin, Zhang, Marika, Ciprotti, F T, Lee, Wijith, Munasinghe, JuDee, Fischer, Peter, Ansell, Gerard, Fox, Hao, Xiong, Edward B, Reilly, Rod, Humerickhouse, Andrew M, Scott
Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 62(6)
ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution, and pharmacokinetics of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::78afb112b99cd100fcaf08a80f22a9d5
https://pubmed.ncbi.nlm.nih.gov/33509972
Zobrazit plný text záznamu
6
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Autor: Shaji Kumar, Andrew W. Roberts, Ahmed Salem, Kevin J. Freise, Cyrille Touzeau, Jia Jia, Asher Chanan-Khan, Paulo Maciag, Elizabeth Punnoose, Wijith Munasinghe, Amit Agarwal, Thierry Facon, Sari H. Enschede, Maria Verdugo, Joel D. Leverson, Jeremy A. Ross, Jaclyn Cordero, Philippe Moreau, Simon J. Harrison
Publikováno v: Blood. 130:2392-2400
The antiapoptotic proteins BCL-2 and myeloid cell leukemia sequence 1 (MCL-1) promote multiple myeloma (MM) cell survival. Venetoclax is a selective, orally bioavailable small-molecule BCL-2 inhibitor; bortezomib can indirectly inhibit MCL-1. In prec
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a64efd4a1cbafd36902707604a249b84
https://doi.org/10.1182/blood-2017-06-788323
Zobrazit plný text záznamu
7
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study
Autor: Philip Komarnitsky, Matthew W. Dudley, Dustin A. Deming, Samuel Y Ngan, Brian G. Czito, Lei He, Mary F. Mulcahy, Wijith Munasinghe, Angela DeLuca, John Zalcberg, Kyle D. Holen, Rajendar K. Mittapalli, Michael Michael, Houman Vaghefi, Gayle S. Jameson
Publikováno v: The Lancet Gastroenterology & Hepatology. 2:418-426
Summary Background Further optimisation of present standard chemoradiation is needed in patients with locally advanced rectal cancer. Veliparib, an oral poly(ADP-ribose) polymerase inhibitor, has been shown to enhance the antitumour activity of chemo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0c3298d5aff4be85deed3990e6975d
https://doi.org/10.1016/s2468-1253(17)30012-2
Zobrazit plný text záznamu
8
Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR
Autor: David M. Hoffman, Wijith Munasinghe, Hong Li, Kyle D. Holen, Rajeev M. Menon, Rajendar K. Mittapalli, Hao Xiong
Publikováno v: Cancer Chemotherapy and Pharmacology. 79:915-922
ABT-414 is an antibody-drug conjugate (ADC) being developed for the treatment of tumors harboring amplification of the epidermal growth factor receptor (EGFR). This study evaluated the potential of ABT-414 to prolong the QT interval as part of the in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b7332a90bc9f5a488e7e2c13dc1aae
https://doi.org/10.1007/s00280-017-3284-y
Zobrazit plný text záznamu
9
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors
Autor: Wijith Munasinghe, Hao Xiong, Mathilde Jalving, Anthony W. Tolcher, Judith de Vos-Geelen, Dennis Bergau, David Hoffman, Michael S. Gordon, Emiliano Calvo, Sven Stodtmann, Diane Medina, Stacie Peacock Shepherd, Silpa Nuthalapati
Publikováno v: Cancer Chemotherapy and Pharmacology
Europe PubMed Central
Cancer Chemotherapy and Pharmacology, 78(5), 1003-1011. SPRINGER
Cancer Chemotherapy and Pharmacology, 78(5), 1003-1011. Springer Verlag
Veliparib (ABT-888) is an orally bioavailable potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1 and PARP-2. This phase 1 study evaluated the effect of veliparib on corrected QT interval using Fridericia's formula (QTcF).Eligible patients with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1aac058b2cdeb30c60cc02e07ff9a28
https://doi.org/10.1007/s00280-016-3156-x
Zobrazit plný text záznamu
10
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial
Autor: Gerald Steven Falchook, Peter Ansell, Wijith Munasinghe, Mark J. Ratain, Razelle Kurzrock, Michael L. Maitland, Sanja Karovic, David S. Hong, Ly M. Nguyen, Elizabeth Hoening, Guinan K. Lian, Joann P. Palma, Linda Janisch, Mark D. McKee, Cherrie K. Donawho, Sarina Anne Piha-Paul, Shekman Wong
Publikováno v: Maitland, ML; Piha-Paul, S; Falchook, G; Kurzrock, R; Nguyen, L; Janisch, L; et al.(2018). Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. BRITISH JOURNAL OF CANCER, 118(8), 1042-1050. doi: 10.1038/s41416-018-0020-2. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/6cc4x3jv
British Journal of Cancer
British journal of cancer, vol 118, iss 8
BACKGROUND:Ilorasertib (ABT-348) inhibits Aurora and VEGF receptor (VEGFR) kinases. Patients with advanced solid tumours participated in a phase 1 dose-escalation trial to profile the safety, tolerability, and pharmacokinetics of ilorasertib. METHODS
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f07e5b8bf47e19deb817360a8551ce2
http://www.escholarship.org/uc/item/6cc4x3jv
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje